- Home
- CGBD vs GHRS Comparison
CGBD vs GHRS Comparison
Compare CGBD & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGBD
- GHRS
- Stock Information
- Founded
- CGBD 2012
- GHRS 2018
- Country
- CGBD United States
- GHRS Ireland
- Employees
- CGBD N/A
- GHRS N/A
- Industry
- CGBD Finance: Consumer Services
- GHRS Biotechnology: Pharmaceutical Preparations
- Sector
- CGBD Finance
- GHRS Health Care
- Exchange
- CGBD Nasdaq
- GHRS Nasdaq
- Market Cap
- CGBD 906.2M
- GHRS 892.0M
- IPO Year
- CGBD 2017
- GHRS 2021
- Fundamental
- Price
- CGBD $12.59
- GHRS $14.85
- Analyst Decision
- CGBD Hold
- GHRS Strong Buy
- Analyst Count
- CGBD 6
- GHRS 9
- Target Price
- CGBD $13.70
- GHRS $30.11
- AVG Volume (30 Days)
- CGBD 598.9K
- GHRS 417.1K
- Earning Date
- CGBD 11-04-2025
- GHRS 11-06-2025
- Dividend Yield
- CGBD 13.19%
- GHRS N/A
- EPS Growth
- CGBD N/A
- GHRS N/A
- EPS
- CGBD 1.14
- GHRS N/A
- Revenue
- CGBD $245,008,000.00
- GHRS N/A
- Revenue This Year
- CGBD $15.09
- GHRS N/A
- Revenue Next Year
- CGBD $5.69
- GHRS N/A
- P/E Ratio
- CGBD $10.99
- GHRS N/A
- Revenue Growth
- CGBD 2.55
- GHRS N/A
- 52 Week Low
- CGBD $11.55
- GHRS $6.72
- 52 Week High
- CGBD $18.64
- GHRS $20.50
- Technical
- Relative Strength Index (RSI)
- CGBD 57.90
- GHRS 58.39
- Support Level
- CGBD $11.55
- GHRS $13.71
- Resistance Level
- CGBD $12.26
- GHRS $15.01
- Average True Range (ATR)
- CGBD 0.26
- GHRS 0.98
- MACD
- CGBD 0.09
- GHRS 0.09
- Stochastic Oscillator
- CGBD 97.64
- GHRS 86.21
About CGBD Carlyle Secured Lending Inc.
Carlyle Secured Lending Inc is a specialty finance company that is a closed-end, externally managed, non-diversified management investment company. It focuses on providing directly originated, financing solutions across the capital structure, with a focus on senior secured lending to middle-market companies located in the United States. The company's investment objective is to generate current income and capital appreciation through debt investments in U.S. middle-market companies.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.